Stock Ratings / Health Care / DCTH / earnings

SENS (38) RCEL (44) ANGO (50) CERS (37) ⌘ Pro Terminal →

Delcath Systems Inc. (DCTH) Next Earnings Date & Expected ±8.2% Move

$14.64 -1.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Delcath Systems Inc. (DCTH) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $508.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DCTH)Realized 20D OHLCV Swing Band: ±8.2%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±8.2% Swing Band

±$1.20 Expected Swing

MODEL EARNINGS SETUP GAUGE

DCTH Quantitative Pre-Earnings Setup: 57/100

Trailing EPS: $4.25 • YoY Revenue Growth: 129.1%

Model Bullish Setup (57/100)Model Risk Weight (43/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$85.2M	$2.7M	$21.0M	86.2%
FY 2024	2024-12-31	$37.2M	-$26.4M	-$19.2M	83.4%
FY 2023	2023-12-31	$2.1M	-$47.7M	-$31.3M	86.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DCTH)

✓Walkthrough of DCTH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DCTH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +41.04%▲ ASCENDING CHANNEL

2026-10-30O $14.64H $15.24L $13.91C $14.64VOL 427.3K

RES: $16.87SUP: $13.76SMA50: $15.66SMA200: $12.34

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DCTH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DCTH Butterfly Map → + Track DCTH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +129.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DCTH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DCTH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DCTH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DCTH)

Health Care Rank #255 of 1016 ⚔️ SENS vs DCTH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DCTH vs. SENS, RCEL, ANGO, CERS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Delcath Systems Inc. (DCTH) ranks #255 by composite RQD confidence (57/100, grade D+) and #447 by equity capitalization ($508.0M). Within this direct 5-issuer industry benchmark cohort, DCTH leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DCTH ACTIVE Delcath Systems Inc.	D+	57/100	—	86.2%	0.8%	-1.48%	$508.0M	Benchmark Subject
SENS Senseonics Holdings Inc.	D-	38/100	—	44.7%	-35.0%	+4.39%	$515.5M	/sens-vs-dcth →
RCEL Avita Medical Inc.	D	44/100	—	82.1%	-35.0%	+1.27%	$516.8M	/rcel-vs-dcth →
ANGO AngioDynamics Inc.	D	50/100	—	54.6%	-23.4%	+1.81%	$519.4M	/ango-vs-dcth →
CERS Cerus Corporation	D-	37/100	—	—	-15.5%	+0.83%	$491.7M	/cers-vs-dcth →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000872912

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Delcath Systems Inc. (DCTH) reported GAAP revenue of $85.2M (+129.1% vs. FY2024 revenue of $37.2M , and +4027.4% cumulative change since FY2023) , GAAP net income of $2.7M, operating cash flow of $22.5M, and free cash flow of $21.0M (+209.0% YoY). On the balance sheet, DCTH closed FY2025 with $123.6M in total assets against $0 in total debt (Altman Z-Score: 20.33, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$85.2M	$2.7M	$22.5M	$21.0M	$123.6M	—
FY2024 (FY)	2024-12-31	$37.2M	-$26.4M	-$18.7M	-$19.2M	$76.6M	—
FY2023 (FY)	2023-12-31	$2.1M	-$47.7M	-$31.3M	-$31.3M	—	—

3. DCTH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DCTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Delcath Systems Inc. (NASDAQ: DCTH) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $14.64 (-1.48% 1D, market cap $508.0M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, DCTH ranks #255 in composite RQD confidence.

How does DCTH compare to SENS and RCEL in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), DCTH carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 86.2%, and ROIC of 0.8%. By comparison, SENS (Senseonics Holdings Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $515.5M) and RCEL (Avita Medical Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $516.8M). Among the 5-stock peer group, DCTH leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DCTH?

Per DCTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000872912), Delcath Systems Inc. generated $85.2M in revenue (+129.1% YoY), $2.7M in net income, and $21.0M in free cash flow against $123.6M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DCTH trading relative to its 50-day, 200-day, and 52-week technical levels?

DCTH last traded at $14.64 (-1.48% on volume of 239,261 shares), positioning the stock -6.51% below its 50-day simple moving average ($15.66) and +18.64% above its 200-day simple moving average ($12.34). Across its 52-week range of $8.12 to $17.42, DCTH sits at the 70.1% percentile with a 14-day RSI of 37.3 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($13.44 to $15.84).